The gut-microbiome as a target for the treatment of schizophrenia: A systematic review and meta-analysis of randomised controlled trials of add-on strategies

SCHIZOPHRENIA RESEARCH

卷:234

Review

Minichino, Amedeo¹  Brondino, Natascia²  Solmi, Marco^3,4  Del Giovane, Cinzia⁵  Fusar-Poli, Paolo^2,4,6,7  Burnet, Philip¹  Cipriani, Andrea^1,8  Lennox, Belinda R.^1,8 

[1] Univ Oxford, Dept Psychiat, Oxford, England

[2] Univ Pavia, Sect Psychiat, Dept Brain & Behav Sci, Pavia, Italy

[3] Univ Padua, Padua Neurosci Ctr, Padua, Italy

[4] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Psychosis Studies, Early Psychosis Intervent & Clin Detect EPIC Lab, London, England

[5] Univ Bern, Inst Primary Hlth Care, Bern, Switzerland

[6] Kings Coll London, Biomed Res Ctr Mental Hlth, Natl Inst Hlth Res NIHR, IoPPN, London, England

[7] South London & Maudsley NHS Natl Hlth Serv Fdn Tr, OASIS Serv, London, England

[8] Warneford Hosp, Oxford Hlth NHS Fdn Trust, Oxford, England

关键词: Schizophrenia;    Gut-microbiome;    Probiotics;    Prebiotics;    Antibiotics;    Minocycline;   

DOI  :  10.1016/j.schres.2020.02.012

来源: Elsevier

【 摘 要 】

The gut-microbiome has been hypothesised as a novel potential target for intervention for schizophrenia. We tested this hypothesis with a systematic review and meta-analysis of studies investigating the efficacy and acceptability of add-on strategies known to affect the gut-microbiome for the treatment of schizophrenia. Following PRISMA guidelines, we searched from inception to August 2019 all the randomised double-blind controlled trials of add-on antibiotics, antimicrobials, pre/probiotics, and faecal transplant in schizophrenia. Primary outcomes were severity of negative symptoms and acceptability of treatment. Data were independently extracted by multiple observers and a random-mixed model was used for the analysis. Heterogeneity was assessed with the I-2 index. We identified 28 eligible trials: 21 investigated antibiotics, 4 antimicrobials (Artemisinin, Artemether, and Sodium Benzoate), 3 pre/probiotics, none faecal transplant. Results showed no effect of D-Cycloserine (10 studies; SMD, -0.16; 95% CI -0.40, 0.08; P = .20; I-2: 28.2%), Minocycline (7 studies; SMD: -0.35; 95% CI -0.70, 0.00; P = .05, I-2:77.7%), other antibiotics (2 studies), probiotics alone (1 study), and Artemisinin (1 study) on negative symptoms of schizophrenia when compared to placebo. Limited evidence suggests efficacy on negative symptoms for Sodium benzoate (2 studies; SMD, -0.63; 95%CI -1.03, -0.23; P < .001; I-2:0%), Artemether (1 study), and probiotics combined with Vitamin D (1 study) when compared to placebo. Acceptability of intervention was similar to placebo. Negative findings were mainly led by antibiotics trials, with paucity of evidence available on pre/probiotics. There is a need of expanding our knowledge on the clinical relevance of gut-microbiome-host interaction in psychosis before engaging in further trials. (C) 2020 Elsevier B.V. All rights reserved.

【 授权许可】

Free